Adult and pediatric IV push medication reference

June 2023



Purpose

The purpose of this document is 2-fold:

- 1) to provide a list of medications commonly administered as intravenous (IV) push or slow IV injection
- 2) to provide a list of medications that can be administered as IV push or slow IV injection to supplement drug shortage mitigation strategies in the setting of bulk IV fluid shortages.

The list of medications provided is not all-inclusive. Clinical judgment and assessment of appropriateness is recommended at the institutional level and may differ based on the clinical scenario (eg, code situations).

Methodology

To provide the 2022 update to this reference, Vizient subject matter experts met to identify medications that are commonly administered via IV push or have recently experienced a drug shortage. From this initial list of 34 medications, IV push or slow IV injection information was obtained and verified with multiple tertiary resources. Once the medication information was collected, Vizient subject matter experts met again to reach consensus on which medications had appropriate literature support for addition to the list. In total, 25 additional medications met criteria to be added the reference list. In 2023, pediatric information was added for medications with available guidance. The list is not inclusive of neonatal administration information. Please refer to the appropriate clinical resources for neonatal information.

Mitigation strategies to conserve IV fluids

This document provides guidance on how members can take advantage of administering medications via IV push or slow IV injection; we have also noted where alternate routes—such as oral (PO) or intramuscular (IM) administration—are an option.

There are several additional strategies that members may wish to implement to conserve IV fluids, including:

- transitioning patients to an oral equivalent when clinically appropriate
- administration of a more concentrated (smaller volume) product wherever possible
- increasing "hang" time of IV fluids
- a summary of mitigation strategies was published by the American Society of Health-System Pharmacy (ASHP)
- discontinuing "to keep open (TKO)" practice and using intermittent line flushing for maintaining patency
- a full list of Vizient mitigation strategies can be accessed on the Vizient website at Drug shortage mitigation strategies

Safety considerations

Surveys <u>conducted by the Institute for Safe Medication Practices</u> (ISMP) have highlighted a number of unsafe practices associated with administering medications IV push, including improper dilution and use of prefilled normal saline flush syringes to dilute medications (often without syringe relabeling).

In recognizing a lack of available guidance and standardized safe practices associated with IV push administration, the ISMP released the ISMP Safe Practice Guidelines for Adult IV Push Medications and also published updated guidance following their survey conducted in 2018. ISMP has a Gap Analysis Tool for Safe IV Push Medication Practices available.

These resources developed by ISMP provide guidance around identifying and targeting the risks associated with current practices that may exist at member institutions, as well as establishing safe and best practices and providing education to healthcare providers.

Medication	Instructions for reconstitution	Dilution instructions for IVP/slow IV inj.	Administration time for IVP/slow IV inj.	Remarks
Acid suppressants				
Esomeprazole (Nexium)	40 mg via l: reconstitute powder with 5 mL NS, LR, or D5W	No additional dilution is necessary	Adult: Administer over at least 3 min Pediatric: No data	 Flush line prior to and after administration with NS, LR, or D5W. IV push administration is approved for treatment of GERD. The manufacturer recommends that pediatric patients receive IV esomeprazole by intermittent IV infusion only.
Famotidine (Pepcid)	20 mg vial: supplied as solution for injection	May administer undiluted or dilute 20 mg (2 mL) vial with NS or another compatible diluent to a total volume of 5 to 10 mL	Adult: Administer over at least 2 min and no faster than 10 mg/min Pediatric ^b : 2 mg/mL over at least 2 min and no faster than 10 mg/min	None of note

Medications with literature support for IV push or slow IV injection^a

Medication	Instructions for reconstitution	Dilution instructions for IVP/slow IV inj.	Administration time for IVP/slow IV inj.	Remarks
Pantoprazole (Protonix)	40 mg vial : reconstitute with 10 mL NS	No additional dilution is necessary	Adult: Administer over at least 2 min Pediatric ^b : 4 mg/mL over at least 2 min	Flush IV line before and after administration with D5W, NS, or LR.
Analgesics				
Fentanyl (Sublimaze)	Supplied as ampules, vials, prefilled syringes, and cartridges supplied as solution for injection	May administer undiluted	Adult: Administer over 1 to 2 min Pediatric ^b : 10 to 50 mcg/mL over at least 3 to 5 min; larger doses over 5 to 10 minutes	Rapid administration may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest. Additional monitoring required.
Hydromorphone (Dilaudid)	Extreme caution should be used to avoid confusion of the highly concentrated injectable product with the less concentrated injectable product	 For the less concentrated formulation - no additional dilution is necessary For high-potency formulation, reconstitute with 25 mL of SWFI to a concentration of 10 mg/mL 	Adult: Administer over 2 to 3 min Pediatric ^b : Same as adult	Rapid administration been associated with an increase in adverse events, especially respiratory depression and hypotension. Additional monitoring required.
Ketorolac (Toradol)	15 mg and 30 mg vials: supplied as solution for injection; 60 mg/2 mL vials for IM injection only	No dilution is necessary	Adult: Administer over 15 s; may also be administered as a slow IV injection distributed evenly over 1 to 2 min. Pediatric ^b : administer over 1 to 5 min	Monitor for signs and symptoms of gastrointestinal upset or bleeding.
Morphine	Supplied as prefilled syringes and cartridges supplied as solution for injection	May dilute to a final concentration of 0.5 to 5 mg/mL	Adult: Administer over 4 to 5 min Pediatric ^b : 0.5 to 5 mg/mL over 4 to 5 min	Products are designed for administration by specific routes. Rapid administration may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest. Additional monitoring required.

Medication	Instructions for reconstitution	Dilution instructions for IVP/slow IV inj.	Administration time for IVP/slow IV inj.	Remarks
Anesthetics / Sedatives				
Diazepam (Valium)	Supplied as vials, prefilled syringes, and cartridges supplied as solution for injection	t	Adult: Administer no faster than 5 mg/min Pediatric ^b : Administer over at	Avoid smaller veins to reduce incidence of venous thrombosis, phlebitis, or local irritation.
	Injection		least 3 min; rate should not exceed 2 mg/min	intation.
Etomidate (Amidate)	Supplied as vials, ampuls, and syringes as solution for injection	Do not dilute	Adult: Administer over 30 to 60 s Pediatric ^b : Same as adult	For general anesthesia induction or procedural sedation. Should be administered by or under the direct supervision of persons trained in administration and management of complications with general anesthesia.
Lorazepam (Ativan)	Supplied as vials, and syringe cartridges as solution for injection	Dilute with SWFI, NS, or D5W. Dilute with an equal volume of compatible solution immediately prior to use.	Adult: Administer over at least 2 min; should not exceed 2 mg/min or 0.05 mg/kg Pediatric ^b : Same as adult	Avoid smaller veins to reduce incidence of venous thrombosis, phlebitis, or local irritation.
	Supplied as vials as solution for injection	For procedural / sedation / anxiolysis use a 1 mg/mL concentration or a dilution of the 1 or 5 mg/mL concentrations.	Adult: For procedural sedation / anxiolysis / amnesia administer over at least 2 min	For general anesthesia induction or procedural sedation should be
			For induction of anesthesia administer over 5 to 15 s	administered by or under the direct supervision of persons trained in administration and management of complications with general anesthesia.
			Pediatric ^b : 1 or 5 mg/mL given over 20 to 30 s for anesthesia induction; should not be administered faster than 2 min in neonates	
Antibiotics				
Ampicillin	125, 250, and 500 mg vials: reconstitute with 5 mL SWFI or	No additional dilution necessary	Adult: Administer doses ≤ 500 mg over 3 to 5 min	Solutions must be used within 1 h of reconstitution
	BWFI		Administer doses > 500 mg over 10 to 15 min	Administering ampicillin more rapidly than recommended
			Pediatric ^b : Same as adult	may result in seizures

Medication	Instructions for reconstitution	Dilution instructions for IVP/slow IV inj.	Administration time for IVP/slow IV inj.	Remarks
	1 g and 2 g vials: reconstitute with 7.4 mL or 14.8 mL SWFI or BWFI, respectively			
Aztreonam (Azactam)	1 g and 2 g vials: reconstitute with 6 to 10 mL SWFI;	No additional dilution necessary	Adult: Administer over 3 to 5 min	None of note
	immediately shake vigorously		Pediatric ^b : Same as adult	
Cefazolin	500 mg vial : reconstitute with 2 mL SWFI. Shake well.	Further dilute reconstituted solution with 5 mL SWFI	Adult: Administer over 3 to 5 min	None of note
	Final conc. = 225 mg/mL		Pediatric ^b : Same as adult and	
	1 g vial: reconstitute with 2.5 mL SWFI. Shake well.		further dilute to a maximum concentration of 100 mg/mL	
	Final conc. = 330 mg/mL			
Cefotaxime (Claforan)	500 mg, 1 g, and 2 g vials: reconstitute with 10 mL SWFI	No additional dilution necessary	Adult: Administer over 3 to 5 min	Avoid rapid injection (< 1 min) due to association with arrhythmias
	Final conc. = 50, 95, and 180 mg/mL, respectively		Pediatric ^b : 180 to 200 mg/mL over 3 to 5 min	
Cefotetan (Cefotan)	1 g vial: reconstitute with 10 mL SWFI	No additional dilution necessary	Adult: Administer over 3 to 5 min	None of note
	Final conc. = 95 mg/mL		Pediatric^b: ≤ 182 mg/mL over 3 to 5 min	
	2 g vial: reconstitute with 10 to 20 mL SWFI			
	Final conc. = 182 or 95 mg/mL, respectively			
Cefoxitin	1 g vial: reconstitute with 10 mL SWFI, BWFI, NS, or D5W	No additional dilution necessary	Adult: Administer over 3 to 5 min	None of note
	Final conc. = 95 mg/mL		Pediatric ^b : 180 mg/mL over 3	
	2 g vial: reconstitute with 10 or 20 mL SWFI, BWFI, NS, or D5W		to 5 min	
	Final conc. = 180 or 95 mg/mL, respectively			

Medication	Instructions for reconstitution	Dilution instructions for IVP/slow IV inj.	Administration time for IVP/slow IV inj.	Remarks
Ceftazidime (Fortaz, Tazicef)	500 mg vial: reconstitute with 5.3 mL SWFI	No additional dilution necessary	Adult: Administer over 3 to 5 min	None of note
	Fortaz final conc. = 100 mg/mL		Pediatric ^b : 100 to 170 mg/mL	
	1 g and 2 g vials: reconstitute with 10 mL SWFI		over 3 to 5 min	
	Fortaz or generic final conc. = 100 and 170 mg/mL, respectively			
	Tazicef final conc. = 95 and 180 mg/mL, respectively			
Cefuroxime	750 mg vial : reconstitute with 8.3 mL SWFI	No additional dilution necessary	Adult: Administer over 3 to 5 min	None of note
	1.5 g vial : reconstitute with 16 mL SWFI		Pediatric ^b : 90 mg/mL over 3 to 5 min	
	Final conc. = 90 mg/mL			
Chloramphenicol	1 g vial : reconstitute with 10 mL SWFI or D5W	No additional dilution necessary	Adult: Administer over at least 1 min	None of note
	Final conc. = 100 mg/mL		Pediatric ^b : 100 mg/mL over at least 1 min	
Colistimethate sodium	150 mg vial : reconstitute with 2 mL SWFI; swirl gently to	No additional dilution necessary	Adult: Administer over 3 to 5 min	The 2019 International Consensus Guidelines for the
	avoid frothing Final conc. = 75 mg/mL colistin base activity		Pediatric ^b : Same as adult	Optimal Use of the Polymixins advise administration over 0.5 to 1 h
Daptomycin (Cubicin, Cubicin RF)	Generic 350 mg vial: reconstitute with 7 mL NS. Allow to stand for 10 min, then gently swirl to obtain completely reconstituted solution. Do not shake or agitate vial vigorously.	No additional dilution is necessary	Adult: Administer over at least 2 min Pediatric: No data	Use of saline-based diluents to reconstitute Cubicin RF results in hyperosmotic solution that may cause infusion site reactions when administered IV push
	Cubicin and generic 500 mg vials: reconstitute with 10 mL NS. Allow to stand for 10 min, then gently swirl to obtain completely reconstituted			

Medication	Instructions for reconstitution	Dilution instructions for IVP/slow IV inj.	Administration time for IVP/slow IV inj.	Remarks
	solution. Do not shake or agitate vial vigorously.			
	Cubicin RF 500 mg vials: reconstitute with 10 mL SWFI or BWFI (do NOT use NS). Rotate or swirl vial for a few minutes, as needed, to reconstitute.			
	Final conc., all products. = 50 mg/mL			
Meropenem (Merrem)	500 mg vial : reconstitute with 10 mL SWFI	No additional dilution is necessary	Adult: Administer over 3 to 5 min	None of note
	1 g vial : reconstitute with 20 mL SWFI		Pediatric ^b : 50 mg/mL over 3 to 5 min	
Nafcillin	1 g vial : reconstitute with 3.4 mL SWFI, BWFI, or NS	Further dilute with 15 to 30 mL SWFI or NS prior to	Adult: Administer over 5 to 10 min	Vesicant. Caution extravasation.
	2 g vial : reconstitute with 6.6 mL SWFI, BWFI or NS	administration (applies to both vial sizes)	appropriate dose in 15 to 30	Caution phlebitis.
	Final conc., both vial sizes= 250 mg/mL		mL of diluent over 5 to 10 min	
Oxacillin	1 g vial : reconstitute with 10 mL of SWFI or NS; shake well	No additional dilution is necessary	Adult: Administer over at least 10 min	Caution phlebitis.
	2 g vial : Add 20 mL of SWFI or NS; shake well		Pediatric ^b : Same as adult	
Antiemetics				
Metoclopramide (Reglan)	Supplied as vials and prefilled syringes as solution for injection	Doses ≤ 10 mg may be given undiluted	Adult: Administer doses ≤ 10 mg undiluted as an IV push over at least 2 min Pediatric ^b : Same as adult	Doses > 10 mg should be diluted in 50 mL compatible solution (preferably NS) and administered via IV piggyback over at least 15 min

Medication	Instructions for reconstitution	Dilution instructions for IVP/slow IV inj.	Administration time for IVP/slow IV inj.	Remarks
Ondansetron (Zofran)	Supplied as vials as solution for injection	Administer undiluted	Adult: Administer over at least 30 s, but preferably over 2 to 5 min	IV push is given for PONV only (single doses)
			Pediatric^b: In children < 40 kg receiving 0.1 mg/kg administer over at least 30 s, but 2 to 5 min is preferred	
Cardiovascular agents				
Diltiazem (Cardizem)	Supplied as vials as solution	Administer undiluted	Adult: Administer over 2 min	Continuous ECG and blood
	for injection. ADD-Vantage powder vials should be reconstituted with 100 mL D5W or NS.		Pediatric ^b : 5 mg/mL over 2 to 5 min	pressure monitoring required
Enalaprilat (Vasotec)	Supplied as vials as solution for injection	May be administered undiluted	Adult: Administer evenly distributed over 5 min	Monitor for precipitous blood pressure drop with first dose
			Pediatric ^b : Same as adult	
Hydralazine	Supplied as vials as solution	Administer undiluted	Adult: Administer over 1 min	Monitor blood pressure every 5
	for injection		Pediatric^b: Administer over 1 to 2 min and no faster than 5 mg/min	min until at desired level. Check every 15 min thereafter throughout crisis.
Labetalol	Supplied as vials, cartridges, and premixed bags as solution for injection	on 2	Adult: Administer over at least 2 min and no faster than 10 mg/min	Although initial bolus dose is often followed by a continuous infusion, providers may instead
			Pediatric ^b : 5 mg/mL over 2 to 3 min and no faster than 2 mg/min	attempt intermittent IV push dosing before converting to a drip or to another agent.
Metoprolol tartrate (Lopressor)	Supplied as ampuls, vials, and	May administer undiluted	Adult: Administer over 1 min	Continuous ECG and blood
	syringe cartridges as solution for injection		Pediatric: No data	pressure monitoring required
Corticosteroids		I	I	I
Dexamethasone (Decadron)	Supplied as vials as solution for injection	May administer 4 mg/mL or 10 mg/mL concentration undiluted	Adult: Administer over at least 1 min Pediatric ^b : Administer over 1 to several minutes	Rapid administration may be associated with perineal burning or tingling. Can dilute to 0.5 mg/mL in NS and administer up to a 10 mg dose

Medication	Instructions for reconstitution	Dilution instructions for IVP/slow IV inj.	Administration time for IVP/slow IV inj.	Remarks
				over 30 s to eliminate the incidence of perineal pruritus.
Hydrocortisone (Solu-Cortef)	Reconstitute 100 mg vial with 2 mL of BWFI or bacteriostatic NS. Act-O-vials reconstituted by pressing down on the plastic activator.	No additional dilution is necessary	Adult: Administer over at least 30 s For doses ≥ 500 mg, administer over 10 min Pediatric ^b : Same as adult	Reconstitute per prescribing information as differences exist between manufacturers.
Methylprednisolone sodium succinate (Solu-Medrol)	Reconstitute with accompanying diluent or bacteriostatic water for injection with benzyl alcohol	No additional dilution is necessary	Adult: Administration rate is variable, several minutes for doses 10 to 40 mg to at least 5 min for doses ≤ 250 mg	Administer high-dose therapy (30 mg/kg) by IV administration over at least 30 min. Rapid administration of high doses
			Pediatric^b: Doses ≤ 1.8 mg/kg or ≤ 125 mg over 1 to several min; for large doses (≥ 500 mg) administer over 10 min	may precipitate cardiac arrhythmia and sudden death.
Diuretics		L		
Acetazolamide (Diamox)	Reconstitute each 500 mg vial with at least 5 mL SWFI	No additional dilution is necessary	Adult: Administer over at least 3 min	IM administration not recommended
			Pediatric^b: 100 mg/mL at a rate no faster than 500 mg/min	
Bumetanide	Supplied as vials as solution for injection	May administer undiluted	Adult: Administer over 1 to 2 min	Oral bioavailability is very good (~80-100%)
			Pediatric ^b : 0.25 mg/mL over 1 to 2 min	
Chlorothiazide (Diuril)	Reconstitute each 500 mg with at least 18 mL of SWFI	No additional dilution is necessary	Adult: Administer over 3 to 5 min (maximum of 500 mg)	None of note
			Pediatric ^b : Administer slowly over 3 to 5 min as a direct injection	

Medication	Instructions for reconstitution	Dilution instructions for IVP/slow IV inj.	Administration time for IVP/slow IV inj.	Remarks
Furosemide	Supplied as vials and prefilled syringes as solution for injection	May administer undiluted	Adult: Administer over 1 to 2 min and no faster than 20 to 40 mg/min Pediatric ^b : Administer over 1 to 2 min and no faster than 0.5 mg/kg/min not to exceed 4 mg/min	Administration faster than 4 mg/min in adults and 0.5 mg/kg/min in pediatrics increases the rate of ototoxicity
Rescue agents				
Atropine	Supplied as vials and prefilled syringes as solution for injection	Administer undiluted	Adult: Administer as a rapid IV push Pediatric ^b : Same as adult	Slow administration may cause paradoxical bradycardia. Additional monitoring of vital signs and / or ECG based on the clinical scenario is required.
Flumazenil (Romazicon)	Supplied as vials as solution for injection	May be administered undiluted. Dilution not required, but may be mixed with D5W, LR, or NS.	Adult: Administer over 15 to 30 s Pediatric ^b : 0.1 mg/mL over 15 s to 30 s; do not exceed 0.2 mg/min	Administer through a freely running IV infusion into a large vein (to minimize pain at injection site) as a series of small injections.
Mesna (Mesnex)	Supplied as vials as solution for injection	Dilute with D5W, NS, LR, D5- 0.2% NS, D5-0.33% NS, or D5-0.45% NS. <i>Final conc. of 20 mg/mL</i>	Adult: Administer over at least 1 min Pediatric ^b : Administer as IV bolus per manufacturer; however, current guidelines recommend administration by short IV infusion over 15 to 30 min or by continuous IV infusion	Refer to specific protocol for administration rate and details.
Naloxone (Narcan)	Supplied as vials, ampuls, cartridges, and prefilled syringes as solution for injection	Can administer undiluted or diluted. For lower doses (0.02 to 0.04 mg), may dilute 1 mL of naloxone 0.4 mg/mL formulation with 9 mL of NS or SWFI for a total volume of 10 mL <i>Final conc. of 0.04 mg/mL</i>	Adult: Administer undiluted as an IV push over 30 s Administer diluted as a slow IV push Pediatric ^b : 0.4 or 1 mg/mL undiluted over 30 s	Duration of narcotic action may exceed that of naloxone.

Medication	Instructions for reconstitution	Dilution instructions for IVP/slow IV inj.	Administration time for IVP/slow IV inj.	Remarks
Miscellaneous				
Cosyntropin (Cortosyn)	Reconstitute 0.25 mg lyophilized powder with 1 mL of NS	Dilute with 2 to 5 mL of NS	Adult: Administer over 2 min Pediatric ^b : Same as adult	Note administration differences between the lyophilized powder and solution
Diphenhydramine (Benadryl)	Supplied as vials, ampuls, and prefilled syringes as solution for injection	May be given undiluted	Adult: Administer no faster than 25 mg/min Pediatric ^b : Same as adult	Monitor for relief of symptoms and mental alertness
Levothyroxine	100 mcg, 200 mcg and 500 mcg vials: reconstitute with 5 mL NS. Shake well.	No additional dilution is necessary	Adult: Administer at a maximum rate of 100 mcg/min Pediatric ^b : Administer as concentration of 40 to 100 mcg/mL in NS over 2 to 3 minutes	None of note

^aThis list is not inclusive of neonatal administration information. Please refer to the appropriate clinical resources for neonatal information.

^bPediatric administration rates provided only; dilution and monitoring information may vary from adults and should be verified with the appropriate clinical resources

Abbreviations: BWFI = bacteriostatic water for injection; D5W = dextrose 5% in water; ECG = electrocardiogram; GERD = gastrointestinal esophageal reflux disease; h = hour; IM = intramuscular; IN = intranasal; IV = intravenous; LR = lactated Ringer solution; min = minute; NA = not applicable; NS = normal saline; PO = by mouth; PONV = postoperative nausea and vomiting; s = second; SC = subcutaneous; SWFI = sterile water for injection

Antibiotic	Reason
Amikacin	Not recommended based on manufacturer recommendations and/or limited data
Azithromycin (Zithromax)	Not for IM or IV bolus administration
Ceftaroline (Teflaro)	Not recommended based on manufacturer recommendations and/or limited data
Ceftazidime / avibactam (Avycaz)	Not recommended based on manufacturer recommendations and/or limited data
Ceftolozane / tazobactam (Zerbaxa)	Not recommended based on manufacturer recommendations and/or limited data
Ciprofloxacin (Cipro)	Not recommended based on manufacturer recommendations and/or limited data
Clindamycin (Cleocin)	Cardiopulmonary arrest and hypotension have been reported following too rapid intravenous administration
Dalbavancin (Dalvance)	Not recommended based on manufacturer recommendations and/or limited data
Doxycycline (Doxy 100)	Not recommended based on manufacturer recommendations and/or limited data
Eravacycline (Xerava)	Not recommended based on manufacturer recommendations and/or limited data
Erythromycin (Erythrocin)	Do not administer IV push or bolus
Imipenem/cilastatin (Primaxin)	Do not administer IV push
Lefamulin (Xenleta)	Not recommended based on manufacturer recommendations and/or limited data
Levofloxacin	Avoid rapid or bolus IV infusion due to risk of hypotension
Linezolid (Zyvox)	Not recommended based on manufacturer recommendations and/or limited data
Meropenem/vaborbactam (Vabomere)	Not recommended based on manufacturer recommendations and/or limited data
Metronidazole (Flagyl)	Not recommended based on manufacturer recommendations and/or limited data
Minocycline (Minocin)	Infuse over 60 min; avoid rapid administration. Injectable route should only be used if oral route not feasible; caution of thrombophlebitis
Moxifloxacin (Avelox)	Infuse over 60 min; do not infuse by rapid or bolus IV infusion
Oritavancin (Orbactiv)	Not recommended based on manufacturer recommendations and/or limited data
Penicillin G (Pfizerpen)	Not recommended based on manufacturer recommendations and/or limited data
Piperacillin / tazobactam (Zosyn)	Not recommended based on manufacturer recommendations and/or limited data
Polymyxin B	Administration of polymyxin B over a period < 30 min is not recommended, and rapid IV injections should be avoided due to the potential for nephro- or neurotoxicity.
Quinupristin / dalfopristin (Synercid)	Infusion should be completed over 60 min; toxicity may be increased with shorter infusion
Rifampin (Rifadin)	Not recommended based on manufacturer recommendations and/or limited data
Tedizolid (Sivextro)	Do not administer as an IV push or bolus
Telavancin (Vibativ)	Not recommended based on manufacturer recommendations and/or limited data
Tigecycline (Tygacil)	Not recommended based on manufacturer recommendations and/or limited data
Trimethoprim-sulfamethoxazole (Bactrim)	Not recommended based on manufacturer recommendations and/or limited data
Vancomycin	Recommended adult infusion rate is a minimum of 30 min for every 500 mg administered

Appendix 1. Antimicrobials that should not be administered as IV push / slow IV injection

Appendix 2. Antimicrobials that may be administered as IV push / slow IV injection in adults

As highlighted in *Hospital Pharmacy* and validated with current package inserts, there are several antibiotics that have primary literature in adults to support IV push administration but for which IV push administration is not FDA approved. These medications include cefepime (Maxipime), ceftriaxone, ertapenem (Invanz), gentamicin, and tobramycin.

While administration via IV push / slow IV injection is not prohibited for the following products, each has associated requirements and/or recommendations that may minimize the benefit(s) generally associated with a push strategy:

- Ampicillin-sulbactam (Unasyn) may be administered via slow injection over 10 to 15 minutes; however, the minimum required product dilution (ie, 33.3 mL for a 1.5 g vial) creates a limitation from a small volume / fluid conservation standpoint.
- The maximum concentration for **fosphenytoin (Cerebyx)** (25 mg PE/mL; ie, 40 mL minimum total volume for a 1000 mg PE dose) also creates a limitation from a small volume/fluid conservation standpoint. Moreover, although fosphenytoin may be administered at a rate of 150 mg PE/min, severe and fatal cardiovascular events (ie, hypotension and cardiac arrhythmias) may occur with rapid administration. Slower administration reduces the incidence of cardiovascular events as well as severity of paresthesias and pruritis.
- **Phenytoin** has a maximum infusion rate of 50 mg/min (ie, 20-minute infusion for 1 g dose). If rapid IV administration is necessary, fosphenytoin is generally preferred.

References:

- 1. Lexi-Drugs. Hudson, OH: Lexicomp. http://online.lexi.com/.
- 2. DailyMed. Bethesda, MD: U.S. National Library of Medicine, National Institutes of Health, Health & Human Services. https://dailymed.nlm.nih.gov/dailymed/.
- 3. Micromedex Solutions. Greenwood Village, CO: Truven Health Analytics. http://micromedex.com/.
- 4. Facts & Comparisons. St. Louis, MO: Wolters Kluwer Health. https://fco.factsandcomparisons.com/.
- 5. AHFS Drug Information STAT!Ref Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. https://online-statref-com/.
- 6. ASHP Injectable Drug Information STAT!Ref Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. https://online-statref-com/.
- 7. Pediatric Injectable Drugs (The Teddy Bear Book) STAT!Ref Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. https://online-statref-com/
- 8. Collins SR. Elsevier's 2022 Intravenous Medications: A Handbook for Nurses and Health Professionals. 38th ed. St. Louis, MO: Elsevier; 2022.
- 9. Spencer S, Ipema H, Hartke P, et al. Intravenous push administration of antibiotics: literature and considerations. Hospital Pharmacy. 2018; 53(3): 157-169.
- Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy*. 2019;39(1):10-39.

Disclaimer: The information contained in this document is intended for informational purposes only and is in no way intended to be a substitute for or in any manner to be construed as medical or clinical advice for any patient in your care. The authors, editors, reviewers, contributors and publishers cannot be held responsible for the accuracy or continued accuracy of the information or for any errors or omissions in the document or for any consequences in the form of liability, loss, injury, or damage incurred as a result of the use and application of any of the information, either directly or indirectly. All medical and clinical decisions regarding any patient's care are the responsibility of the patient's physician.

The information contained throughout this document is confidential and proprietary in nature to Vizient, Inc. Use or distribution of this information without Vizient's express written permission is prohibited.



Vizient, Inc. 290 E. John Carpenter Freeway Irving, TX 75062-5146 (800) 842-5146

> To learn more, please contact Vizient Center for Pharmacy Practice Excellence, Evidence-Based Medicine Group at pharmacyquestions@vizientinc.com.

As the nation's largest member-driven health care performance improvement company, Vizient provides solutions and services that empower members to deliver high-value care by aligning cost and quality in the critical areas of clinical, operational, and supply chain performance.